Kura Oncology, Inc.
For the period ended Jun 30, 2025. Filed Aug 7, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 7, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
INDEX TO EXHIBITS
| Exhibit Number | Description | Filed Herewith | Incorporated by Reference herein from Form or Schedule | Filing Date | SEC File/Reg. Number |
|---|---|---|---|---|---|
| 3.1 | Amended and Restated Certificate of Incorporation of the Registrant, as amended. | 8-K(Exhibit 3.1) | 6/14/2017 | 001-37620 | |
| 3.2 | Amended and Restated Bylaws of the Registrant. | 8-K(Exhibit 3.2) | 6/14/2017 | 001-37620 | |
| 4.1 | Form of Common Stock certificate. | 8-K(Exhibit 4.1) | 3/12/2015 | 000-53058 | |
| 4.2 | Warrant to Purchase Stock issued by the Registrant on April 27, 2016 to Oxford Finance LLC. | 10-Q(Exhibit 4.3) | 8/10/2016 | 001-37620 | |
| 4.3 | Form of Warrant Agreement issued by the Registrant on November 2, 2022 to certain Lenders. | 10-K (Exhibit 4.3) | 2/23/2023 | 001-37620 | |
| 4.4 | Amended and Restated Warrant Agreement, dated November 29, 2022, by and between the Registrant and Hercules Capital, Inc. | 10-K(Exhibit 4.4) | 2/23/2023 | 001-37620 | |
| 4.5 | Warrant Agreement, dated November 29, 2022, by and between the Registrant and Hercules Capital IV, L.P. | 10-K(Exhibit 4.5) | 2/23/2023 | 001-37620 | |
| 4.6 | Form of Pre-Funded Warrant. | 8-K(Exhibit 4.1) | 1/26/2024 | 001-37620 | |
| 4.7** | Registration Rights Agreement, dated January 26, 2024, by and among the Registrant and the persons party thereto. | 8-K(Exhibit 10.2) | 1/26/2024 | 001-37620 | |
| 10.1 | First Amendment to Lease, dated May 6, 2025, by and between the Registrant and BP3-SD5 5510 Morehouse Drive LLC. | X | |||
| 10.2 | First Amendment to Lease, dated June 6, 2025, by and between the Registrant and HCP Life Science REIT, Inc. | X | |||
| 10.3+ | Kura Oncology, Inc. Amended and Restated 2014 Equity Incentive Plan and Forms of Option Agreement, Notice of Exercise and Stock Option Grant Notice thereunder. | 8-K(Exhibit 99.1) | 6/6/2025 | 001-37620 | |
| 10.4*** | Co-Promotion and Medical Affairs Agreement, dated June 27, 2025, by and between the Registrant and Kyowa Kirin, Inc. | X | |||
| 31.1 | Certification of Principal Executive and Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | X | |||
| 32.1* | Certifications of Principal Executive and Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. 1350. | X | |||
| 101.INS | Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. | X | |||
| 101.SCH | Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents. | X | |||
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101.INS). | X | |||
- Indicates management contract or compensatory plan.
- The certification attached as Exhibit 32.1 accompanies this Quarterly Report on Form 10-Q pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, and shall not be deemed “filed” by the Registrant for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.
** Schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. A copy of any omitted schedule and/or exhibit will be furnished to the SEC upon request.
*** Certain portions of this exhibit have been omitted pursuant to Item 601 of Regulation S-K.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.